OrbiMed-linked entities exercise 210K CRVS options
Corvus Pharmaceuticals director and 10% owner Peter A. Thompson reported multiple option exercises linked to OrbiMed-affiliated entities.
Rhea-AI Filing Summary
Corvus Pharmaceuticals director and 10% owner Peter A. Thompson reported multiple option exercises linked to OrbiMed-affiliated entities. On 01/28/2026, stock options covering 210,000 shares of common stock were exercised at strike prices ranging from $0.965 to $15, resulting in 210,000 shares of common stock reported as directly owned.
An additional 8,609,091 shares of common stock are reported as indirectly owned through OrbiMed Private Investments V, LP and related OrbiMed entities. The filing states that Thompson, OrbiMed Advisors and OrbiMed Capital GP V LLC each disclaim beneficial ownership of these securities except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
210,000 shares exercised/converted
Exercise
27 txns
Insider
Thompson Peter A.
Role
Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 30,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 30,000 | $15.00 | $450K |
| Exercise | Common Stock | 15,000 | $9.70 | $146K |
| Exercise | Common Stock | 15,000 | $12.50 | $188K |
| Exercise | Common Stock | 15,000 | $3.61 | $54K |
| Exercise | Common Stock | 15,000 | $2.00 | $30K |
| Exercise | Common Stock | 15,000 | $3.27 | $49K |
| Exercise | Common Stock | 15,000 | $2.74 | $41K |
| Exercise | Common Stock | 15,000 | $2.60 | $39K |
| Exercise | Common Stock | 15,000 | $0.9899 | $15K |
| Exercise | Common Stock | 15,000 | $0.965 | $14K |
| Exercise | Common Stock | 15,000 | $2.49 | $37K |
| Exercise | Common Stock | 15,000 | $1.64 | $25K |
| Exercise | Common Stock | 15,000 | $2.12 | $32K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 210,000 shares (Direct);
Common Stock — 8,609,091 shares (Indirect, See Footnotes)
Footnotes (16)
- F1. Pursuant to an agreement with OrbiMed Advisors LLC ("OrbiMed Advisors") and OrbiMed Capital GP V LLC ("GP V"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP ("OPI V"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- F2. These securities are held of record by OPI V. GP V is the general partner of OPI V, and OrbiMed Advisors, a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors.
- F3. Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
- F4. The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from March 22, 2016, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- F5. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2018 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
- F6. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
- F7. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
- F8. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date.
- F9. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
- F10. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
- F11. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date.
- F12. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
- F13. The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- F14. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
- F15. The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- F16. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
FAQ
What insider transaction did CRVS disclose for Peter A. Thompson?
Corvus Pharmaceuticals disclosed that stock options associated with director and 10% owner Peter A. Thompson were exercised for 210,000 shares of common stock on 01/28/2026. The resulting shares and related economic benefits are tied to OrbiMed-affiliated investment entities under pre-existing agreements.
What types of derivatives were exercised in this CRVS Form 4 filing?
The Form 4 shows exercises of multiple stock options (rights to buy common stock) on 01/28/2026. Each option series had its own exercise price and vesting schedule, with underlying shares converting into common stock as the options became exercisable under prior grant terms.
At what prices were Corvus Pharmaceuticals (CRVS) options exercised on 01/28/2026?
On 01/28/2026, stock options were exercised at a range of strike prices including $15, $9.7, $12.5, $3.61, $2, $3.27, $2.74, $2.6, $0.9899, $0.965, $2.49, $1.64, and $2.12, each converting into common shares.
Which entity officially holds the large indirect CRVS position in this Form 4?
The 8,609,091 indirectly owned shares of Corvus Pharmaceuticals common stock are held of record by OrbiMed Private Investments V, LP. OrbiMed Capital GP V LLC is its general partner, and OrbiMed Advisors LLC is the managing member that exercises investment and voting power through its management committee.
AI-generated analysis. How Rhea-AI works. Not financial advice.
